Close

Anti-EGFR (Matuzumab) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-WFY6580)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to 4-1BB(CD137), OX40 and CD3ζ signaling domains. And the vector product was designed for the treatment of multiple myeloma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EGFR
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Plasma membrane
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells and binds to a high-affinity ligand (4-1BB) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMS, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound.CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • Matuzumab
  • Host
  • Rabbit
  • Target Species
  • Human
  • Gene Name
  • Epidermal Growth Factor Receptor
  • Synonyms
  • EGFR;EGFR; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1; Erb-B2 Receptor Tyrosine Kinase 1; Proto-Oncogene C-ErbB-1; EC 2.7.10.1; ERBB1; ERBB; HER1; Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog); Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian);

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data FCM

Fig.1 EGFR expression detected by Matuzumab on FACS analysis of A431, Caski and C33A cells.

CAR Construction : Latest CAR Construction

Fig.1 EGFR expression detected by Matuzumab on FACS analysis of A431, Caski and C33A cells.

Student's t test * P < 0.05, when compared to controls.

Meira, D. D., Almeida, V. H., Mororó, J. S., Caetano, M. S., Nóbrega, I. P., Batista, D., ... & Ferreira, C. G. (2011). Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab. Molecular cancer, 10(1), 1-13.

CAR scFv data FCM

Fig.2 Combination of matuzumab and gemcitabine induces tumor cell apoptosis and cell cycle arrest in vitro.

CAR Construction : Latest CAR Construction

Fig.2 Combination of matuzumab and gemcitabine induces tumor cell apoptosis and cell cycle arrest in vitro.

All measurements were performed in triplicate.

Kleespies, A., Ischenko, I., Eichhorn, M. E., Seeliger, H., Amendt, C., Mantell, O., ... & Bruns, C. J. (2008). Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine. Clinical Cancer Research, 14(17), 5426-5436.

CAR scFv data ELISA

Fig.3 Binding of mAbs cetuximab and matuzumab to peptide arrays.

CAR Construction : Latest CAR Construction

Fig.3 Binding of mAbs cetuximab and matuzumab to peptide arrays.

Data are represented as mean±s.d.

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517-4527.

CAR scFv data FCM

Fig.4 Renca-lacZ/EGFR cells were incubated with mAbs cetuximab or matuzumab either without pretreatment, or after pretreatment of cells with a 20-fold molar excess of anti-peptide antibodies or pre-immune serum as indicated.

CAR Construction : Latest CAR Construction

Fig.4 Renca-lacZ/EGFR cells were incubated with mAbs cetuximab or matuzumab either without pretreatment, or after pretreatment of cells with a 20-fold molar excess of anti-peptide antibodies or pre-immune serum as indicated.

Control cells were treated only with secondary antibody.

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517-4527.

CAR scFv data FuncS

Fig.5 Phage binding to scFv fragments of cetuximab or matuzumab were selected in independent sets of experiments from libraries of M13KE bacteriophage displaying randomized linear 7mer, linear 12mer or cyclic 7mer (C7C).

CAR Construction : Latest CAR Construction

Fig.5 Phage binding to scFv fragments of cetuximab or matuzumab were selected in independent sets of experiments from libraries of M13KE bacteriophage displaying randomized linear 7mer, linear 12mer or cyclic 7mer (C7C).

Cyclic 7mer (C7C) peptides using IPTG-induced cultures of E. coli HB101 harboring pIB-Tx-scFv(225) or pIB-Tx-scFv(72000).

Hartmann, C., Müller, N., Blaukat, A., Koch, J., Benhar, I., & Wels, W. S. (2010). Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 29(32), 4517-4527.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-EGFR (Matuzumab) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-WFY6580). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.